12th Apr 2007 11:54
Sinclair Pharma PLC12 April 2007 Sinclair Pharma PLC ("Sinclair" or the "Company") Proposed move to the Official List from AIM 12 April 2007, Godalming, UK. Following the announcement by Sinclair, (AIM:SPH), on 15 March 2007 of its intention to apply for admission to the OfficialList of the UKLA (the "Official List"), application has now been made for theCompany's issued ordinary shares to be admitted to the Official List and to betraded on London Stock Exchange plc's market for listed securities ("Admission")and for the cancellation of the Company's issued ordinary shares on theAlternative Investment Market of London Stock Exchange plc ("AIM"). It isintended that Admission will become effective at 8.00 a.m. on 16 April 2007 andthat trading in the Company's shares on AIM will cease at the same time. Sinclair has also made application for admission to trading on the Eurolist ofEuronext Paris, the regulated market of Euronext Paris SA ("Euronext Paris"),and expects to commence trading on that market on, or soon after, 19 April 2007. The Directors believe that the move to the Official List is appropriate to thegrowth and ambition of the Company. The new listings are expected to increaseliquidity in the ordinary shares, and enhance the domestic and internationalprofile of the Company. In recent years, the Company has expanded itsinternational presence, and now has significant and expanding activities incontinental Europe. A secondary listing on Euronext Paris will reflect theCompany's growing commercial presence in these territories. Copies of the Prospectus are also available for one month from the Company'sregistered office (Sinclair Pharma plc, Godalming Business Centre, Woolsack Way,Godalming, Surrey, UK, GU7 1XW) or at http://www.sinclairpharma.com/investors.php. Alternatively the Prospectus is available for inspection at theUKLA's document viewing facility, which is situated at: Financial ServicesAuthority 25 The North Colonnade Canary Wharf London E14 5HS. For further information please contact: Sinclair Pharma plc Tel: +44 (0) 1483 410 600Dr Michael Flynn, CEOJerry Randall, CFOZoe McDougall, Director of Communications Piper Jaffray Tel: +44 (0) 20 3142 8700David RasoulyWill Carnwath Capital MS&L Tel +44 (0)20 7307 5340Mary Clark, Halina Kukula Notes to Editors: Sinclair Pharma plc Sinclair Pharma plc is an international specialty pharmaceutical company. Ithas a growing sales and marketing operation that is already present in France,Italy, UK, Spain and Portugal, and a complementary marketing partner networkthat spans more than 65 countries. Sinclair has proven expertise in acquiring or developing commercially attractiveand undervalued products, registering these products and bringing them to marketwithin a short time frame. The company focuses on niche therapeutic areas andits current portfolio includes products for dermatological conditions and oralhealth. Other languages For versions of this press release in French, German or Japanese please [email protected] "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma